Kalaris and AlloVir Announce Stockholder Approval of Merger

Core Points - AlloVir stockholders approved all proposals at a Special Meeting, including the merger with Kalaris Therapeutics [1] - The merger is expected to close soon, with the combined company to be renamed Kalaris Therapeutics, Inc. and trade under the ticker "KLRS" on Nasdaq [2] - Kalaris focuses on developing treatments for retinal diseases, particularly TH103, an investigational therapy for neovascular Age-related Macular Degeneration [2] - AlloVir specializes in allogeneic T cell immunotherapy aimed at restoring immunity against viral diseases in immunocompromised patients [3] Company Overview - Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to retinal disease treatments [2] - TH103 is a novel anti-VEGF therapy developed by Dr. Napoleone Ferrara, designed for improved VEGF inhibition and longer retention in the retina [2] - Kalaris is currently conducting a Phase 1 clinical trial for TH103, with plans to expand its application to other retinal diseases like Diabetic Macular Edema and Retinal Vein Occlusion [2] Industry Context - The merger between Kalaris and AlloVir represents a strategic consolidation in the biopharmaceutical sector, particularly in the field of immunotherapy and retinal disease treatment [1][2] - The focus on retinal diseases highlights a growing market demand for innovative therapies addressing prevalent conditions affecting vision [2]